Wills Eye Hospital

Running trials

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

  NCT07425522· Phase 1· Genentech, Inc.· Source

• Active, not recruiting

  CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

  NCT07449923· Phase 3· EyePoint Pharmaceuticals, Inc.· Source

• Recruiting

  Neoadjuvant Tebentafusp for Uveal Melanoma

  NCT06414590· Phase 2· Thomas Jefferson University· Source

• Recruiting

  A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

  NCT06822738· Phase 3· AbbVie· Source

• Active, not recruiting

  An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06625398· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  Electrical Stimulation for the Treatment of Glaucoma

  NCT05626491· Stanford University· Source

• Active, not recruiting

  A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

  NCT05224102· Phase 4· Genentech, Inc.· Source

• Recruiting

  Clarifying the Optimal Application of SLT Therapy Trial

  NCT04967989· Phase 3· University of Pittsburgh· Source

• Active, not recruiting

  A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

  NCT03941379· Aura Biosciences· Source

• Recruiting

  Novel Glaucoma Diagnostics

  NCT00286637· Wills Eye· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Glaucoma3 recruiting
• Diabetic eye disease1 recruiting
• High blood pressure1 recruiting
• Macular degeneration1 recruiting

Closed trials

• Recruiting

  Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

  NCT07220876· Avisi Technologies Inc.· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

  NCT05397600· Phase 3· Laboratoires Thea· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  Evaluating Home Testing Devices for the Management of Glaucoma

  NCT05325996· Wills Eye· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

  NCT04832724· Phase 2· AbbVie· Source

• Completed

  Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

  NCT04417530· Phase 2· Aura Biosciences· Source

• Withdrawn

  RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

  NCT03629899· Wills Eye· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Glaucoma47 works · 7 trials
• Diabetic eye disease18 works · 4 trials
• Macular degeneration14 works · 3 trials